Open Orphan, Elektron Technology and Glen Goodman on Crypto
If you find this podcast useful please give it a rating and review on iTunes by clicking here
Do you want to get instant company alerts to the front screen of your smartphone? Download the Vox Markets app here: www.VoxMarkets.co.uk/app
On today's Vox Markets Podcast: Open Orphan, Elektron Technology and Glen Goodman on Crypto
Cathal Friel, Chief Executive Officer of Open Orphan (ORPH) talks about the appointment to the board of David Kelly as an Independent Non-Executive Director.
Open Orphan plc is a European-focussed, rare and orphan drug consulting services platform. The Company consists of four elements: a European clinical research organisation and consultancy; an orphan drug services business; a Virtual Rep and Data Access Platform consisting of physicians and key opinion leaders; and a Health Data Platform to partner with Patient Advocacy Groups. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.
Keith Daley, Executive Chairman of Elektron Technology (EKT) discusses the sale of their Bulgin business for £105 million and the plans for the business going forward.
Elektron Technology creates and develops products and services that Connect, Monitor and Control. The operational and financial resources of Bulgin, its established business allow it to invest in Checkit, an early stage high growth business that provides a real-time operations management system. In addition the Group owns a designer of ophthalmic screeners, Elektron Eye Technology.
(Interview starts at 13 minutes 5 seconds)
Glen Goodman, former ITV News Business correspondent and now author of, "The Crypto Trader", provides some insight into the world of crypto currency trading.
(Interview starts at 21 minutes 18 seconds)
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.